Allarity casts a wider net for stenoparib in ovarian cancer, with no new data yet
The US biotech has amended its mid-stage ovarian cancer study to admit two more kinds of patient, but disclosed no enrolment numbers, endpoints or timelines.
17 Nov 2026 · Allarity Therapeutics, Inc. ALLR · Company news
Allarity Therapeutics has changed the design of its ongoing mid-stage trial of stenoparib, an oral drug that blocks both PARP and tankyrase, so that it now admits more kinds of advanced ovarian cancer patient. The company announced the amendment on 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news